A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Osteo-Site Vertebral Balloon and Complex VCF Treatment Toolbox Launches

Osteo-Site Vertebral Balloon for vertebral augmentation has launched. The news was announced today by IZI Medical Products, a manufacturer of interventional radiology devices.

Osteo-Site Vertebral Balloon completes IZI’s offering of Vertebral Compression Fracture (“VCF”) treatment options, which include Osteo-Site Vertebroplasty, Osteo-Site Balloon Kyphoplasty, Blazer Curved Needle Augmentation, and Kiva PEEK Implant-based augmentation.

“We want to enable our physicians to choose the most clinically appropriate solution for their patients when treating vertebral compression fractures,” said Greg Groenke, CEO, IZI Medical. “We have created an integrated portfolio of VCF treatment devices with the ability to switch between different treatment options with ease.”

“IZI has completed the VCF toolbox: Kiva for metastatic VCF’s, Blazer Curved Needle for targeted cement deployment in sclerotic bone and blastic metastases, and now Osteo-site Balloon and curved needle for osteoporotic fractures. IZI has made it simple to switch between all of them which gives me intra-operative flexibility,” said Dr. Kieran Murphy, Professor of Radiology at University Health Network Toronto.

The new Osteo-site Vertebral Balloon is designed to create a cavity within the vertebral body. Currently, the balloon is available in 10G and 11G sizes. “The Osteo-site balloon will be paired with our Duro-Ject Injector, which provides maximum control and feedback during injection and minimizes radiation exposure with a long flexible tubing,” said Jovie Soriano, SVP Marketing and Business Development, IZI Medical. “We have also made improvements to our Murphy access needles based on physician feedback that will be included in the Osteo-Site Balloon kit.”

IZI Medical’s VCF portfolio will be supported by a dedicated sales team of direct representatives and independent distributors to drive market penetration in the United States, followed by expansion into Europe.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy